Barclays raised the firm’s price target on Avidity Biosciences (RNA) to $62 from $59 and keeps an Overweight rating on the shares. The firm views the company’s Q2 report as largely incremental.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences Signs Manufacturing Agreement with Lonza
- Avidity Biosciences reports Q2 EPS ($1.21), consensus (96c)
- Avidity Biosciences: Promising Pipeline and Strategic Developments Drive Buy Rating Amid Potential Novartis Takeover Interest
- Disney reports Q3 beat and NFL deal, Uber authorizes $20B buyback: Morning Buzz
- Avidity up over 20% to $46.05 after FT report of buyout interest